AGP14 for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
AGP14 may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed AGP14 in detail.
, Identification of Potential Semisynthetic Andrographolide Derivatives to Combat COVID-19 by Targeting the SARS-COV-2 Spike Protein and Human ACE2 Receptor– An In-silico Approach, Biointerface Research in Applied Chemistry, doi:10.33263/BRIAC132.155
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causal factor for the current deadly infectious disease CoVID-19. There is no specific drug available for treating COVID-19 other than some vaccines approved for prevention. However, a lot of research is in progress to prove the anti-COVID-19 potential of natural and synthetic compounds. Objective: The present study was aimed to identify the anti-COVID-19 potential of andrographolide (AGP) derivatives by in-silico molecular interaction study. Seventeen AGP derivatives were screened for drug-likeness, ADME, and toxicity profile using in-silico online tools. Then the filtered AGP were subjected to molecular docking using the PyRx tool integrated with AutoDock Vina software. Compounds AGP 15, 14, and 10 have been identified as promising binding molecules for both S and ACE2, preventing the interaction between S and ACE2. AGP-15 had shown a −8.4 Kcal/mol binding/docking score for S, AGP-10 and 14 showed a -8.3 and -8.2 Kcal/mol binding/docking score for ACE2. Overall results indicated that AGP derivatives 15 and 14 might be the best candidates to battle COVID-19. However, further studies like dynamic molecular studies and pharmacological screenings are essential to confirm the stability and action potential of AGP derivatives 14 and 15 as a lead against COVID-19.